- Sharonann Lynch, HIV & TB Advisor, MSF Access Campaign
Of the estimated 600,000 people who were newly infected with MDR-TB in 2016, only 130,000 began treatment. An estimated 240,000 people died from the disease the same year. Although two promising newer drugs, bedaquiline and delamanid, have been on the market for more than four years, patients’ access to them remains unacceptably limited. As of February 2018, only 16,069 people worldwide had received bedaquiline and only 1,247 people had received delamanid. In addition to scale-up, reporting of treatment outcomes is needed to inform future World Health Organization’s treatment guidelines.
Four Years and Counting: https://www.msfaccess.org/MDR-TB-issue-brief-2017
Out of Step: TB Policies in 29 Countries, 3rd Ed. (2017): https://www.msfaccess.org/outofstep2017
MSF has been involved in TB care for 30 years, often working alongside national health authorities to treat patients in a wide variety of settings, including chronic conflict zones, urban slums, prisons, refugee camps and rural areas. In 2016, MSF supported more than 20,000 TB patients on treatment, including 2,700 patients with drug-resistant forms of TB.
Press & Communications Officer
MSF Access Campaign
Médecins Sans Frontières
Ph: +41 22 849 9334
M: +41 79 203 13 02
Skype: Shailly.17 |Twitter: @shaillytweeting